NYSEAMERICAN:BPMX

Biopharmx - BPMX Stock Forecast, Price & News

$0.14

-0.01 (-6.85%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.13
▼
$0.15
50-Day Range: N/A
52-Week Range: $0.25
▼
$1.18

Volume: 46.89 million shs
Average Volume: 2.15 million shs
Market Capitalization: $2.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Biopharmx (NYSEAMERICAN:BPMX) Stock

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Receive BPMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter.

BPMX Stock News Headlines

July 19, 2022 | globenewswire.com

Global Acne Treatment Market, By Therapeutic Class, By Formulation, By Type, By Acne Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 - GlobeNewswire

July 17, 2022 | seekingalpha.com

Timber Pharmaceuticals, Inc. (TMBR) Stock Price Today, Quote & News - Seeking Alpha

July 14, 2022 | streetinsider.com

Form DEF 14A Vivos Therapeutics, Inc. For: Jul 14 - StreetInsider.com

March 31, 2022 | globenewswire.com

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results - GlobeNewswire

March 16, 2022 | finance.yahoo.com

Acne Drugs Global Market Report 2022 - Yahoo Finance

December 23, 2021 | benzinga.com

2021 Metabolic Partnering Global Report - In-depth Understanding of Metabolic Deal Trends Since 2014 - Be - Benzinga

December 15, 2021 | globenewswire.com

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology - GlobeNewswire

November 16, 2021 | streetinsider.com

Form 10-Q Timber Pharmaceuticals, For: Sep 30 - StreetInsider.com

October 13, 2021 | streetinsider.com

Venus Concept Appoints Ross J. Portaro as President of Global Sales - StreetInsider.com

October 13, 2021 | streetinsider.com

Form 8-K Venus Concept Inc. For: Oct 05 - StreetInsider.com

October 11, 2021 | globenewswire.com

Acne Vulgaris Pipeline: Therapeutic Assessment, Emerging Drugs, Key Pharma Players, Clinical Trials, and Growth Prospects Analysis - GlobeNewswire

August 31, 2021 | streetinsider.com

Form PRER14A NEXTGEN HEALTHCARE, INC. - StreetInsider.com

August 23, 2021 | streetinsider.com

Form PRE 14A NEXTGEN HEALTHCARE, INC. For: Oct 13 - StreetInsider.com

August 10, 2021 | globenewswire.com

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results - GlobeNewswire

July 22, 2021 | streetinsider.com

Gelteq Appoints Seasoned Pharma and Tech Executive, James Pekarsky, as Chief Financial Officer - StreetInsider.com

May 12, 2021 | ca.finance.yahoo.com

Prothena: Q1 Earnings Snapshot - Yahoo Canada Finance

May 11, 2021 | globenewswire.com

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results - GlobeNewswire

May 4, 2021 | streetinsider.com

Form S-3 Timber Pharmaceuticals, - StreetInsider.com

April 27, 2021 | seekingalpha.com

Timber Pharmaceuticals: Funding Only Into Q3 2021, But Some Hidden Value Remains - Seeking Alpha

February 25, 2021 | globenewswire.com

Acne Drugs Market Research Report by Acne Type, by Drug Class, by Drug Type, by Route of Administration - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswire

December 22, 2020 | streetinsider.com

Evolent Health (EVH) Confirms Agreement With Engaged Capital - StreetInsider.com

December 17, 2020 | streetinsider.com

Form 8-K Timber Pharmaceuticals, For: Dec 17 - StreetInsider.com

November 12, 2020 | streetinsider.com

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2020 Financial Results - StreetInsider.com

October 15, 2020 | streetinsider.com

Know In depth about Global 3D Printed Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2025 - StreetInsider.com

September 29, 2020 | streetinsider.com

The Global Demand for 3D Printed Drugs Market Anticipated to Surge Amid the rapidly Increasing COVID-19 Infections, KDMI Report - StreetInsider.com

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BPMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter.

BPMX Company Calendar

Last Earnings: 12/10/2019
Today: 8/14/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:BPMX
Previous Symbol: NYSE:BPMX
CUSIP: N/A
CIK: N/A
Web: www.biopharmx.com
Phone: +1-650-8895020
Fax: N/A
Employees: 17
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 18,278,000
Free Float: N/A
Market Cap: $2.49 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. David S. Tierney M.D. (Age 55)
Pres, CEO, CFO and Director
Dr. Kin Foong Chan (Age 45)
Exec. VP of Research & Technology
Dr. José Zayas
Sr. VP of Operations
Ms. Joyce Goto (Age 45)
VP, Chief Accounting Officer & Controller
Ms. AnnaMarie Daniels
Exec. VP of Clinical & Regulatory Affairs

Key Competitors

View All Competitors

BPMX Stock - Frequently Asked Questions

How have BPMX shares performed in 2022?: Biopharmx's stock was trading at $0.3330 at the start of the year. Since then, BPMX shares have decreased by 59.2% and is now trading at $0.1360.
View the best growth stocks for 2022 here.
How were Biopharmx's earnings last quarter?: Biopharmx Corp (NYSEAMERICAN:BPMX) announced its quarterly earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.64) by $0.96.
When did Biopharmx's stock split?: Biopharmx's stock reverse split before market open on Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What other stocks do shareholders of Biopharmx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN).

What is Biopharmx's stock symbol?: Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
How do I buy shares of Biopharmx?: Shares of BPMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biopharmx's stock price today?: One share of BPMX stock can currently be purchased for approximately $0.14.
How much money does Biopharmx make?: Biopharmx (NYSEAMERICAN:BPMX) has a market capitalization of $2.49 million.
How can I contact Biopharmx?: Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The official website for the company is www.biopharmx.com. The biotechnology company can be reached via phone at +1-650-8895020.

This page (NYSEAMERICAN:BPMX) was last updated on 8/14/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources